Clinical Trials in Hungary

• A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Capsules Compared to Intravenously (IV) Infused Rituximab Plus IV Infu… Ended
  2024-510965-41-00 Phase III Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (… AbbVie Deutschland GmbH & Co. KG
• A Study to Evaluate the Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis Ended
  2024-511260-84-00 Phase II Atopic Dermatitis Apogee Therapeutics Inc.
• Extension trial for adults with high cholesterol who completed a MK-0616 clinical trial Ended
  2023-504922-20-00 Phase III Hypercholesterolemia Merck Sharp & Dohme LLC
• Efficacy and safety of subcutaneous dupilumab in participants with asthma/asthmatic wheeze aged 2 to <6 years Ended
  2023-504331-41-00 Phase III Respiratory tract diseases - Wheezing, Asthma Sanofi-Aventis Research & Development
• A Study to Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants with Previously Untreated High-… Ended
  2023-510178-15-00 Phase III High-risk Large B-cell Lymphoma Celgene Corp.
• A study to find how well Dazodalibep works and how safe it is in participants with Sjögren’s Syndrome Ended
  2023-503923-24-00 Phase III Sjögren’s Syndrome With Moderate-toSevere Symptom State Horizon Therapeutics Ireland Designated Activity Company
• A Double-blind, Placebo-controlled, Phase IIb, Multi-center, Twelve-week Prospective Study to Evaluate the Efficacy and Safety of Gemlapodec… Ended
  2023-505086-83-00 Phase II Tourette Syndrome Noema Pharma AG
• A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants with Severe Alopecia Areata Ended
  2023-505061-82-01 Phase III Alopecia Areata AbbVie Deutschland GmbH & Co. KG
• A Phase 3 study of Etentamig vs Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (3L+ RRMM Monot… Ended
  2023-506668-15-00 Phase III Relapsed or Refractory Multiple Myeloma (RRMM) AbbVie Deutschland GmbH & Co. KG
• A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participan… Ended
  2023-503666-23-00 Phase III Neovascular age-related macular degeneration Abbvie Deutschland GmbH & Co. KG
• A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu… Ended
  2022-502781-24-01 Phase III ASCVD - Atherosclerotic Cardiovascular Disease Merck Sharp & Dohme LLC
• A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin alone and how safe it is in adults with chronic kidn… Ended
  2023-506457-38-00 Phase III Chronic kidney disease (CKD) and hypertension. Astrazeneca AB
• A Randomized, Double Blind, Active-Controlled Study on Efficacy and Safety of TEV-56248 in Patients with Asthma Ended
  2023-505435-12-00 Phase III Asthma Teva Branded Pharmaceutical Products R&D LLC
• Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i… Ended
  2023-506906-38-00 Phase III Follicular Lymphoma AbbVie Deutschland GmbH & Co. KG
• A study to evaluate the safety and the activity of S095029 as a part of combination therapy in advanced gastroesophageal junction/gastric ca… Ended
  2023-507995-33-00 Phase I/II MSI-H/dMMR Gastric cancer Institut De Recherches Internationales Servier IRIS
• A study to investigate long-term safety and tolerability of itepekimab in participants with COPD Ended
  2023-508085-15-00 Phase III Chronic Obstructive Pulmonary Disease Sanofi-Aventis Recherche & Developpement
• Effect of Tranexamic Acid Oral Solution 5% in patients treated with direct oral anticoagulants or vitamin K antagonists and undergoing a sin… Ended
  2023-503719-13-00 Phase III Prevention of clinically relevant bleeding events in patient… Hyloris Developments
• A Phase 3 Placebo-Controlled Study With Randomized Dose Up/Dose Down Extension Period Investigating the Efficacy, Safety, and Tolerability o… Ended
  2022-502518-98-00 Phase III nonsegmental vitiligo Pfizer Inc.
• A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLV… Ended
  2023-507456-69-00 Phase II Atopic Dermatitis Nektar Therapeutics
• Randomised, placebo-controlled Phase II proof of concept study of efficacy and safety of a novel rifamycin SV in situ gelling rectal solutio… Ended
  2023-506917-23-00 Phase II patients with mild to moderate left-sided ulcerative colitis Cosmo Technologies Limited
• Selective Treatment of Oral Povorcitinib in Vitiligo Study 2 (STOP-V2) Ended
  2023-506011-18-00 Phase III Vitiligo Incyte Corp.
• Bomedemstat vs Best Available Therapy (BAT) for Essential Thrombocythemia Ended
  2023-504865-21-00 Phase III Essential Thrombocythemia patients who have an inadequate re… Merck Sharp & Dohme LLC
• A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab Injections Before and After Surgery for the Treatment of Adult Patients wit… Ended
  2023-505928-59-00 Phase III Triple Negative or Hormone Receptor low/HER2-negative Breast… Astrazeneca AB
• A Phase 3 Study of DB-1303 vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer Ended
  2023-507333-17-00 Phase III HER2-low, Hormone Receptor Positive, Metastatic Breast Cance… Dualitybio Inc.

Showing 601–624 of 1,251 trials